Dysport^® demonstrates long-lasting symptom control between injections: significant reductions in muscle tone and increased range of motion, with time to retreatment of 12–16* weeks or longer.^1–6

More than a third of patients (36.9%) did not require retreatment until Week 16 or later after their previous Dysport^® injection in a pivotal trial.⁴

Up to 32%^† of patients did not require retreatment until Week 16 or later over repeat Dysport^® treatment cycles.^3,4

With Dysport^®, significant reductions in muscle tone were sustained through Week 12.^1,3,7

Dysport^® can provide an increased range of motion, with most patients responding to treatment⁵

At the maximum approved dose of 1000 U, Dysport^® contains 5.38 ng of active neurotoxin⁶

^*Dysport^® should not be administered more frequently than every 12 weeks.

^†15.2–32%.^3,4

^‡Cycle 1 (n=224) included patients who were treated with Dysport^® in the DB phase and entered the OLE phase. Cycles 2 (n=297) and 3 (n=224) included patients who received Dysport^® in the OLE, including those who received placebo in the DB phase.⁴

^§P<0.0001 vs placebo for both doses.^1,7

^¶Numbers at baseline.^1,7

^#P<0.05 vs placebo for 1500 U dose.³

^**The mITT population included ITT patients with primary endpoint data at Week 6 of cycle 2.5 The ITT population included all patients with a defined primary treatment target limb who received ≥1 Dysport^® injections and ≥1 days of guided self-rehabilitation contract therapy.⁵

^††UL CXA defined as the sum of XA values against the resistance of elbow flexors, wrist flexors and extrinsic finger flexors.⁵

^‡‡LL CXA defined as the sum of XA values against the resistance of soleus and gastrocnemius muscles.⁵

_§§Amount of active neurotoxin at the maximum FDA-approved dose, according to a study that assessed the quantity and light chain activity of BoNT-A products, whereby 150 kDA BoNT-A was quantified by sandwich ELISA and light chain activity was assessed by the EndoPep assay. In both assays, results were assessed for the products against recombinant 150 kDa BoNT-A.⁶

References:

1. Gracies J-M, et al. Lancet Neurol. 2015;14(10):992–1001.
2. Gracies J-M, et al. Muscle Nerve. 2018;57(2):245–254.
3. Gracies J-M, et al. Neurology. 2017;89(22):2245–2253.
4. Esquenazi A, et al. Front Neurol. 2020;11:576117.
5. Gracies J-M, et al. J Neurol Phys Ther. 2021;45(3):203–213.
6. Field M, et al. Toxins. 2018;10(12):535.
7. Gracies J-M, et al. Lancet Neurol. 2015;14(10):992–1001. (Table S3; supplementary material).

Abbreviations:

BoNT-A, botulinum toxin type A; CXA, composite range of active motion; DB, double-blind; ELISA, enzyme-linked immunosorbent assay; FDA, US Food and Drug Administration; Inco-BoNT-A, incobotulinumtoxinA; ITT, intention-to-treat; LL, lower limb; MAS, Modified Ashworth Scale; mITT, modified intention-to-treat; OLE, open-label extension; Ona-BoNT-A, onabotulinumtoxinA; U, units; UL, upper limb; XA, active range of motion.

For further information, please refer to the Prescribing Information or the Summary of Product Characteristics.